New NICE Guideline for Type 2 Diabetes Recognises Benefits From Newer Agents for Blood Glucose Control (y 2)

NICE guidance is developed using the expertise of the NHS and the wider healthcare community including NHS staff, healthcare professionals, patients and carers, industry and the academic world.

Other agents reviewed in the NICE guideline on newer agents for blood glucose in type 2 diabetes include the Thiazolidinediones, GLP-1 mimetic and long-acting human insulin analogues.

About Merck Sharp & Dohme Limited

Merck Sharp & Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey, USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.

'Januvia'(R) is a Registered Trademark of Merck & Co., Inc., Whitehouse Station, New Jersey, USA.

    
    References:
    (1) National Institute for health and Clinical Excellence. Type 2
        diabetes: newer agents for blood glucose in type 2 diabetes. Review
        of NICE technology appraisal guidance 66. May 2009. www.nice.org.uk
    (2) Diabetes Atlas. http://www.eatlas.idf.org/
    (3) Diabetes Impact Survey Report, MSD Diabetes.
    (4) Krobot KJ, Stein PP, Alen S et al. Lower risk of hypoglycaemia with
        sitagliptin compared to glipizide when added to ongoing metformin
        therapy: An analysis based on A1C-adjusted event rates. Abstract
        presented at the 68th Scientific Sessions of the American Diabetes
        Association, June 2008, San Francisco.
    (5) IMS Health, NPA(TM) Weekly, TRxs: data on file
    (6) 'Januvia' (sitagliptin). Summary of Product Characteristics. MSD UK
        2007
    (7) Diabetes UK. Guide to diabetes.
        http://www.diabetes.org.uk/Guide-to-diabetes/complications/s...

    
    For further information, please contact:
    Diane Wass / Louise Barr
    Merck Sharp & Dohme Limited
    Office: +44(0)1992-457272 / 462126
    diane_wass@merck.com
    louise_barr@merck.com
    Georgie Griffith / Katie Armson
    Cohn & Wolfe
    Office: +44(0)20-7331-5369 / 5330
    georgie.griffith@cohnwolfe.com
    katie.armson@cohnwolfe.com

For further information, please contact: Diane Wass / Louise Barr, Merck Sharp & Dohme Limited, Office: +44(0)1992-457272 / 462126, diane_wass@merck.com, louise_barr@merck.com; Georgie Griffith / Katie Armson, Cohn & Wolfe, Office: +44(0)20-7331-5369 / 5330, georgie.griffith@cohnwolfe.com, katie.armson@cohnwolfe.com